rs17696736 — NAA25 NAA25 G/A

Intronic tag SNP at the 12q24 locus that captures SH2B3/LNK regulatory variation, increasing risk for type 1 diabetes, juvenile idiopathic arthritis, and other autoimmune diseases; also associated with modest effects on lipid levels and serum urate

See your personal result for NAA25

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

NAA25 rs17696736 — The 12q24 Autoimmune Locus Tag

The rs17696736 variant sits inside an intron of NAA25 (N-alpha-acetyltransferase 25) on chromosome 12q24, but its disease associations are better understood through the wider 12q24 locus11 12q24 locus
A cluster of genes on chromosome arm 12q, including SH2B3/LNK and ATXN2, that shows unusually broad association with autoimmune, metabolic, and cardiovascular conditions. rs17696736 acts as a tag SNP for this region, meaning it travels in linkage disequilibrium22 linkage disequilibrium
Physical co-inheritance of nearby variants; when one is measured the other can be inferred without direct genotyping with functional variants in neighboring genes. In genome-wide association studies, carrying the G allele has been consistently associated with elevated risk for type 1 diabetes and juvenile idiopathic arthritis, and minor associations with serum lipids and urate have also been reported.

The Mechanism

The principal causal gene at this locus is thought to be SH2B3 (also called LNK), which encodes an adaptor protein that suppresses cytokine receptor signaling downstream of JAK233 suppresses cytokine receptor signaling downstream of JAK2
LNK physically binds JAK2 and thrombopoietin receptor, acting as a brake on white blood cell proliferation and cytokine amplification loops. When SH2B3 function is reduced through regulatory variants tagged by rs17696736-G, the brake on immune cell proliferation weakens, predisposing toward excessive lymphocyte and myeloid cell activation. A second gene, ATXN2 (ataxin-2), lies immediately adjacent to SH2B3 and regulates RNA processing; variants in this gene are hypothesized to contribute to the metabolic arm of the 12q24 phenotype — insulin resistance and lipid dysregulation — while SH2B3 variants primarily explain the autoimmune arm.

NAA25 itself is the auxiliary (scaffolding) subunit of the NatB N-terminal acetyltransferase complex, which co-translationally acetylates the N-terminus of roughly 20% of all human proteins44 acetylates the N-terminus of roughly 20% of all human proteins
N-terminal acetylation modulates protein stability, localization, and protein-protein interactions; substrates include Bax, actin, and multiple metabolic enzymes. Whether the intronic variant directly alters NAA25 expression or is purely a surrogate for nearby functional variation remains unresolved. The available evidence points to SH2B3 as the primary driver of autoimmune association at this locus.

The Evidence

The 12q24 locus was first confirmed as a T1D susceptibility region by Todd et al. in a 2007 Nature Genetics GWAS55 Todd et al. in a 2007 Nature Genetics GWAS
Four new chromosome regions confirmed: 12q24, 12q13, 16p13, 18p11; P_overall ≤ 1.15×10⁻¹⁴ for 12q24 spanning >4,000 T1D cases. The rs17696736 SNP specifically was tested in an Estonian case-control study by Douroudis et al.66 Douroudis et al.
154 T1D patients vs. 230 controls; rs17696736 G allele: OR=1.53, 95% CI 1.14–2.04, p=0.0046, which confirmed that G allele carriers had a 53% higher T1D risk compared to AA homozygotes. A follow-up Estonian study by Kisand and Uibo77 Kisand and Uibo
65 LADA, 154 T1D, 260 T2D patients and 229 controls found rs17696736 remained part of an optimized T1D prediction model alongside HLA-DQB1, insulin gene, PTPN22, CTLA4, and CD226 variants, but notably did NOT contribute to LADA prediction — underscoring that this locus tags classic type 1 diabetes autoimmunity rather than the more slowly progressive autoimmune diabetes spectrum.

In juvenile idiopathic arthritis, rs17696736 was independently replicated across two studies: Prahalad et al. 200988 Prahalad et al. 2009
445 JIA cases, 643 controls; OR=1.20, p=0.041 and Thompson et al. 201099 Thompson et al. 2010
>6,000 participants; OR=1.19, p=2.59×10⁻⁵. This supports the concept that the 12q24 locus confers shared autoimmune susceptibility across multiple conditions — a pattern now recognized for several immune regulatory loci. A 2010 childhood stroke study found no association between rs17696736 and ischemic stroke in children, placing this variant squarely in the autoimmune rather than vascular domain.

Secondary GWAS associations include modest effects on HDL, LDL, and total cholesterol (beta ~0.02 standard deviations per allele), and an inverse association with serum urate levels — G carriers have marginally lower urate, potentially reflecting SH2B3/ATXN2 effects on purine metabolism. Effect sizes are small and clinical relevance is modest compared to the autoimmune associations.

Practical Implications

For G allele carriers, the primary actionable implication is awareness of autoimmune disease susceptibility — specifically type 1 diabetes and inflammatory arthritis. The G allele frequency in European populations (~40–43%) means heterozygosity (AG) is actually the most common genotype in Europeans, whereas GG homozygosity (~13–18%) carries the largest additive risk increment. East Asian populations are almost entirely AA at this locus, consistent with lower T1D rates in East Asian populations.

Unlike strongly autoimmune-specific HLA variants, the 12q24 signal has a modest per-allele OR (~1.2–1.5 per study), meaning it contributes as one piece of a polygenic T1D risk picture rather than dominating risk individually. It is most useful in the context of a multi-locus T1D genetic risk score.

Interactions

rs17696736 operates in the same 12q24 locus as rs653178 (ATXN2/SH2B3), which is the lead GWAS SNP for multiple autoimmune conditions including T1D, celiac disease, hypertension, and asthma. These two SNPs are in strong linkage disequilibrium in European populations. The combined effect of SH2B3 dysregulation (autoimmune predisposition) and ATXN2 variation (metabolic predisposition) is hypothesized to jointly explain why T1D patients commonly show features of both autoimmunity and metabolic dysfunction.

Epistatic interactions have been noted with PTPN22 (rs2476601) — the tyrosine phosphatase that acts in the same T-cell signaling pathway. rs2476601 is one of the strongest non-HLA T1D risk variants (OR ~1.7–2.0 for heterozygotes); when combined with 12q24 risk variants, the cumulative probability of T1D rises meaningfully above either variant alone, though the specific compound genotype data for rs17696736 + rs2476601 is not available in the literature.

Genotype Interpretations

What each possible genotype means for this variant.

AA Non-Risk Genotype Normal

No copies of the 12q24 risk allele; standard autoimmune disease susceptibility at this locus

You carry two copies of the A allele at rs17696736, the common reference allele at the 12q24 locus. This means you do not carry the G-allele tag of SH2B3 regulatory variants at this position. Your genetic risk for type 1 diabetes, juvenile idiopathic arthritis, and related autoimmune conditions from this locus is at or below population average. Approximately 41–43% of people of European descent share this genotype; in East Asian populations it is nearly universal (>99%).

AG One Risk Allele Intermediate

One copy of the 12q24 G risk allele; modestly elevated type 1 diabetes and autoimmune arthritis risk

rs17696736 is an intronic tag SNP for the 12q24 chromosomal region, where the key functional gene is SH2B3 (LNK), an immune regulatory adaptor that suppresses JAK2- driven lymphocyte and myeloid cell expansion. When tagged regulatory variants reduce SH2B3 function, the brake on immune cell proliferation weakens, lowering the threshold for autoreactive T and B cell expansion. The per-allele OR of ~1.2–1.5 for T1D reflects a genuine additive effect — each additional G allele incrementally raises risk. The locus was first confirmed in a large T1D GWAS (Todd et al. 2007, Nat Genet) and the rs17696736 SNP specifically confirmed in Estonian T1D cohort data (Douroudis 2010).

GG Two Risk Alleles High Risk

Two copies of the 12q24 G risk allele; meaningfully elevated type 1 diabetes and autoimmune arthritis susceptibility

GG homozygosity at rs17696736 places you in the tail of the 12q24 risk distribution. The SH2B3/LNK brake on JAK2-driven lymphocyte expansion is most attenuated in homozygous risk-allele carriers. This creates a state of lower threshold for autoreactive immune activation. The locus was confirmed as a T1D risk signal (P_overall ≤ 1.15×10⁻¹⁴; Todd et al. 2007), and the specific variant was validated in Estonian T1D cohorts. The same locus has been independently replicated for JIA in two separate studies. Secondary metabolic associations (modest lipid effects, marginal urate reduction) reflect the neighboring ATXN2 gene's influence on energy and purine metabolism, but these effects are small compared to the autoimmune signal.

Importantly, this locus does NOT predict LADA (latent autoimmune diabetes in adults) — it is specific to classic childhood-onset type 1 diabetes autoimmunity, according to Kisand and Uibo 2012. This suggests the SH2B3 pathway is relevant to rapid-onset autoimmune beta-cell destruction rather than slower LADA progression.